 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...2728293031323334353637...143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, magrolimab (GS-4721) / Ono Pharma, Gilead
Leveraging CRISPR-Cas9 screening platform for discovery of novel tumor intrinsic phagocytosis modulators (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1752;
Conclusions We successfully established and implemented multiple macrophage and tumor cell co-culture screening platforms, and systematically revealed tumor intrinsic regulators of phagocytosis, uncovering multiple known and novel therapeutic targets regulating vulnerability of tumor cells to macrophage-mediated phagocytosis. Our proprietary high-throughput phagocytosis CRISPR screening platform provides an unbiased and rapid solution to study macrophage and tumor cell interactions and discover novel targets for cancer therapy.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Antibody-lectin bispecifics for glyco-immune checkpoint blockade (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1517;
Conclusions These studies provide proof-of-principle for AbLecs as a first-in-class, modular platform technology enabling blockade of glyco-immune checkpoints for cancer immunotherapy. Download figure Open in new tab Download powerpoint Abstract 1209 Figure 1 Graphical abstract
- YH32364 / Yuhan Corp, ABL Bio
YH32364 (ABL104), a novel EGFR/4-1BB bispecific antibody exhibits potent antitumor efficacy with an excellent safety profile (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1366;
Conclusions YH32364 exhibited potent in vitro and in vivo efficacy and it was well tolerated and safe potentially due to tumor-localized T cell activation. These results suggest that YH32364 could be a promising therapeutic for EGFR-overexpressing cancer patients, especially with EGFR drug resistance.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, ES004 / Elpiscience
Treatment of anti-SIRPα in combination with anti-TAA exerts superior anti-tumor activity (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1107;
Conclusions In summary, the functional anti-SIRPα mAb ES004-B5 has great potential to be used in combinations with multiple anti-TAA antibodies in cancer treatment. We are currently advancing the development of ES004-B5 into clinical candidate.
- FT538 / Fate Therap
Interim Phase I clinical data of FT538, an off-the-shelf, multiplexed-engineered, iPSC-derived NK cell therapy, combined with monoclonal antibodies in patients with advanced solid tumors (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1045;
P1
Treatment consists of two, 29-day treatment cycles, each consisting of 3 days outpatient conditioning chemotherapy (cyclophosphamide 500 mg/m 2 and fludarabine 30 mg/m 2 ), followed by 3 outpatient once-weekly doses of FT538; mAbs are administered at standard dose and schedule...Dose escalation is based on a modified toxicity probability interval algorithm dose-escalation design with a starting dose level of 100 million FT538 cells/dose in combination with avelumab or pembrolizumab in PD-L1-expressing solid tumors; trastuzumab in HER2-expressing tumors; or cetuximab in colorectal cancer, squamous head and neck or lung cancers, or epidermal growth factor receptor-mutated lung cancer...Dose escalation is ongoing. Conclusions Interim clinical data, including safety and tolerability and initial anti-tumor activity, from the ongoing Phase I dose-escalation study of FT538 combined with anti-PD-1/L1 or ADCC-competent mAbs in advanced solid tumors will be presented at the conference.
- CDX-1140 / Celldex, Keytruda (pembrolizumab) / Merck (MSD)
Results from a Phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_923;
P1
Further studies are warranted. Trial Registration NCT03329950 Ethics Approval The study was reviewed and approved by the following institutional review boards: Providence Health & Services Institutional Review Board for Earle A. Chiles Research Institute/Providence Cancer Institute; approval number/ID: PHS IRB #2017000532 WCG-IRB for Gabrail Cancer Center, Georgia Cancer Specialists, HonorHealth Research Institute, and Nebraska Cancer Specialists; approval number/ID: 20172645 Rhode Island Hospital IkRB#1 for Legorreta Cancer Center at Brown University/Rhode Island Hospital/Lifespan Cancer Center; approval number/ID: LS-P-Camp Office of Regulatory Affairs of the University of Pennsylvania for Hospital of the University of Pennsylvania; approval number/ID: UPCC 18917 Memorial Sloan Kettering Cancer Center Institutional Review Board/Privacy Board; approval number/ID: 18-225 Participants gave informed consent before taking part in the study.
- Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono, subasumstat (TAK-981) / Takeda
A CIVO intratumor microdose Phase 0 Trial of subasumstat (TAK-981) in combination with cetuximab or avelumab reveals Type 1 Interferon induction and immune activation in head and neck cancer patients (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_899;
P1
They also provide mechanistic rationale for further evaluating combinations of subasumstat with anti-EGFR antibodies and/or checkpoint blockade in human tumors. Trial Registration NCT04065555: Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
- BYON4228 / Byondis
BYON4228, a pan-allelic SIRPα blocking antibody with a favorable pre-clinical safety profile, enhances anti-tumor immunity in vitro and in vivo (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_830;
Clinical studies are planned to start in 2022. Ethics Approval Appropriate ethics approvals were present before commencing studies in vivo.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Real-world treatment patterns among patients with locally advanced head and neck squamous cell carcinoma (LA HNSCC) in a community oncology setting (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_789;
The study protocol was granted an exemption and waiver of informed consent by the US Oncology Institutional Review Board on the basis of the use of deidentified patient data. View this table: View inline View popup Download powerpoint Abstract 454 Table 1 Patient demographic and clinical characteristics Download figure Open in new tab Download powerpoint Abstract 454 Figure 1 Time to next treatment by treatment group
- EDIT-202 / Editas Medicine, Bayer
EDIT-202, a multiplexed AsCas12a edited iPSC differentiated iNK, displays a mature phenotype, high KIR expression, and ADCC towards multiple solid tumor lines. (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_650;
Conclusions In conclusion, iPSC derived NK cells (iNK) have the unique advantage of being an off-the-shelf, and fully characterizable cell therapy amenable to multiplexed gene editing to enhance anti-tumor activity. EDIT-202 demonstrates a mature phenotype which translates to a highly potent and persistent iNK cell for potential treatment of multiple solid tumor types.
- AB-101 / Artiva Biotherap
Evaluation of AB-101, an Allogeneic Cord Blood-derived Natural Killer (NK) Cell Therapy, as an ADCC Enhancer in Hematologic and Solid Tumors (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_643;
P1/2
In addition, in vivo efficacy of AB-101 and AB-101 in combination with rituximab demonstrated enhanced median survival in the Raji xenograft model and AB-101 in combination with trastuzumab led to enhanced survival in the SKOV-3 xenograft model...AB-101 is currently in a Ph1 clinical trial to evaluate the safety and anti-tumor activity alone and in combination with rituximab in patients with relapsed or refractory NHL (ClinicalTrials.gov: NCT04673617 ). Ethics Approval All animal work was conducted under reviewed IACUC protocol and with approval of an IACUC committee at each center where the studies took place.
- Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
iPSC-derived NK cells engineered with a novel TGFβ signal redirector receptor exhibit enhanced performance against solid tumors (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_596;
Conclusions Collectively, the data illustrate that a customized TGFβ-SRR construct can redirect TGFβ-mediated suppression and potentiate effector cell function to enhance the anti-tumor activity of iNK cells. This novel synthetic receptor represents an innovative strategy to enable adoptively-transferred cell therapy to overcome the immunosuppressive TME for the successful treatment of bulky tumors.
- |||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Circulating tumor DNA: Acquired Genomic Alterations (Acq-GA's) in 1st line w/Cetuximab in mCRC: CtDNA Analysis of the CALGB/SWOG-80405 Trial (Alliance). Only 6.6% developed Acq-GAs in 1st line anti-EGFR vs 62.0% in later-line of anti-EGFR. https://t.co/XUzU4qEhvu #CancerResearch @SWOG #crcsm #cancer (Twitter) - Oct 6, 2022
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: NIR-II Navigation with an EGFR-Targeted Probe Improves Imaging Resolution and Sensitivity of Detecting Micrometastases in Esophageal Squamous Cell Carcinoma Xenograft Models. (Pubmed Central) - Oct 5, 2022
In conclusion, cetuximab-IR800 with high specificity for ESCC was first used in NIR-II surgical navigation. This probe showed better imaging resolution and higher sensitivity in detecting subtle metastases derived from an orthotopic ESCC model than NIR-I, which indicates that NIR-II has promise in guiding precise surgery for ESCC patients.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: RTOG-1016: Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer (clinicaltrials.gov) - Oct 5, 2022
P3, N=987, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
This probe showed better imaging resolution and higher sensitivity in detecting subtle metastases derived from an orthotopic ESCC model than NIR-I, which indicates that NIR-II has promise in guiding precise surgery for ESCC patients. Unknown status --> Active, not recruiting
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Review, Journal, Liquid biopsy: Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer. (Pubmed Central) - Oct 4, 2022
The utility of liquid biopsy to detect resistance mutations against anti-EGFR therapy has recently been described. This approach may constitute a new standard in the decision algorithm for targeted CRC therapy.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma (clinicaltrials.gov) - Oct 4, 2022
P2, N=35, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
This approach may constitute a new standard in the decision algorithm for targeted CRC therapy. Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, avutometinib (VS-6766) / Verastem
Enrollment open, Trial initiation date, Metastases: A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Oct 4, 2022
P1b/2, N=53, Recruiting, Sponsor: University of Chicago
Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Sep 2023 Not yet recruiting --> Recruiting | Initiation date: Apr 2022 --> Aug 2022
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Inspirational to see my friend, colleague, GI SPORE member & @VUMC_Cancer faculty @bhumi_singh present @AACR #AACRcrc22 meeting on his fantastic work to overcome cetuximab resistance in #colorectalcancer! @jordanberlin5 @CathyEngMD @KristenCiombor @TheDrChuck (Twitter) - Oct 4, 2022
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Interest of cetuximab in advanced or metastatic squamous cell carcinoma in failure of anti PD-1 (poster space) - Oct 3, 2022 - Abstract #JDP2022JDP_511;
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Real-world evidence, Real-world, Metastases: A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Oct 2, 2022
P=N/A, N=10, Recruiting, Sponsor: Xijing Hospital
Not yet recruiting --> Recruiting | Initiation date: Apr 2022 --> Aug 2022 Trial primary completion date: May 2022 --> Sep 2022
- | Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis. (Pubmed Central) - Oct 2, 2022
Considering the efficacy, safety, compliance, and economic profiles collectively, one of the standard first-line regimens, literally TPEx should be recommended as the best choice for R/M-HNSCC. Furthermore, more head-to-head trials are needed to confirm those findings.
- || Review, Journal: Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies. (Pubmed Central) - Oct 1, 2022
Suggested approaches are described, using up-to-date literature, to aid clinicians in navigating the integration of newer targeted agents with hypofractionated palliative and/or ablative metastatic RT. Further prospective studies are required.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response. (Pubmed Central) - Oct 1, 2022
Interestingly, cetuximab alone or combined with the IC dose of cisplatin can induce an antitumor immune response in vivo, but not when combined with a high dose of cisplatin. (4) Our observations suggest that the EXTREME protocol or cetuximab alone are capable, under conditions of moderate apoptosis induction, of eliciting the mobilization of the immune system and an anti-tumor immune response in HNSCC.
- | paclitaxel / Generic mfg.
Journal: A novel ligand-modified nanocomposite microparticles improved efficiency of quercetin and paclitaxel delivery in the non-small cell lung cancer. (Pubmed Central) - Oct 1, 2022
Furthermore, this system also has low toxicity and good biocompatibility. These results demonstrated that P/Q@CNMPs could be a potential intelligent targeting strategy used for chemo-resistant NSCLC therapies.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Immune checkpoint inhibitors in locally advanced and recurrent/metastatic head and neck cancer: An updated meta-analysis of phase II/III randomized controlled trials (Room 324) - Oct 1, 2022 - Abstract #ESMOAsia2022ESMO_Asia_409;
Conclusions ICI improve OS when compared to chemotherapy alone however PFS was not significant. There was decrease grade 3 AE with ICI.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Impact of EXTREME regimen and cetuximab, cisplatin, and paclitaxel-based regimen on clinical and humanistic outcomes in patients suffering from recurrent or metastatic head and neck squamous cell cancer (Room 324) - Oct 1, 2022 - Abstract #ESMOAsia2022ESMO_Asia_408;
We found the QALYs were statistically significant and showed better tolerance in cohort II patients compared to cohort I. Conclusions The cetuximab, cisplatin, and paclitaxel-based regimen was better tolerated and has shown significant improvement in patients' QALYs compared to the EXTREME regimen which was comprised of cetuximab, cisplatin, and 5-fluorouracil. However, this regimen did not improve clinical outcomes compared to the EXTREME regimen in the patient suffering from R/M HNSCC.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Drastic response to cetuximab in metastatic eccrine porocarcinoma with EGFR amplification (Summit 2) - Oct 1, 2022 - Abstract #ESMOAsia2022ESMO_Asia_399;
As an initial chemotherapy, carboplatin and docetaxel were administered every 3 weeks...Based on this result, cetuximab (400 mg/m 2 once, then 250 mg/m 2 per week) in association with 5-FU/LV (200 mg/m 2 leucovorin, 400 mg/m 2 bolus fluorouracil, and 2400 mg/m 2 infusional fluorouracil per 2 weeks) were administered...Table 1. Comprehensive genomic profiling by FoundationOne ®CDx
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preoperative chemotherapy prior to primary tumor resection for colorectal cancer patients with asymptomatic resectable primary lesion and synchronous unresectable liver-limited metastases (RECUT): A prospective, randomized, controlled, multicenter clinical trial (Hall 404) - Oct 1, 2022 - Abstract #ESMOAsia2022ESMO_Asia_358;
P3
Chemotherapy regimens consisting of either mFOLFOX6 plus cetuximab, mFOLFOX6 plus bevacizumab or mFOLFOX6 alone were assessed according to the RAS genotype and patient affordability...Conclusions Pre-PTR chemotherapy improves PFS in the treatment of these asymptomatic CRLMs patients over upfront PTR. Pre-PTR chemotherapy should remain the preferred reference treatment for these eligible patients.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Multi-omics signature for identification of RAS wild-type colorectal cancer liver metastases sensitive to anti-EGFR therapy (Summit 2) - Oct 1, 2022 - Abstract #ESMOAsia2022ESMO_Asia_336;
P4
In this study, we aimed to develop and validate a multi-omics deep learning model to predict cetuximab efficacy in RAS wild type mCRC patients...Conclusions The multi-omic signature can serve as an intermediate surrogate marker of anti-EGFR treatment sensitivity and survival. The signature outperformed known biomarkers in providing an early prediction of treatment sensitivity and could be used to Ras wild type mCRC treatment decisions.
- | Zolinza (vorinostat) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Efficacy of vorinostat-sensitized intraperitoneal radioimmunotherapy with Cu-labeled cetuximab against peritoneal dissemination of gastric cancer in a mouse model. (Pubmed Central) - Sep 30, 2022
No significant toxicity signals were observed in all treatment groups. Our data suggest that vorinostat is a potentially effective radiosensitizer for use during the treatment of peritoneal dissemination of gastric cancer by ipRIT with Cu-cetuximab.
- ||| fulzerasib (GFH925) / GenFleet Therap
Enrollment open, Trial primary completion date, Combination therapy, Metastases: A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 30, 2022
P1, N=80, Recruiting, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Our data suggest that vorinostat is a potentially effective radiosensitizer for use during the treatment of peritoneal dissemination of gastric cancer by ipRIT with Cu-cetuximab. Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2022 --> Aug 2023
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers. (Pubmed Central) - Sep 29, 2022
Patients with mCRC receiving cetuximab + FOLFIRI who presented with high plasma HGF levels had significantly worse PFS and OS. Cetuximab resistance induced by HGF was mediated by AKT and ERK activation and overcome by MET inhibition in vitro.
- || Review, Journal: Studying molecular signaling in major angiogenic diseases. (Pubmed Central) - Sep 29, 2022
In clinical therapeutics, target therapy focusing on discovery of novel anti-angiogenic agents like bevacizumab, cetuximab, sunitinib, imatinib, lenvatinib, thalidomide, everolimus etc., to block or inhibit the angiogenesis pathway is well explored in recent times. In this review, we will discuss about the molecular signaling pathways involved in major angiogenic diseases in detail.
- | 5-fluorouracil / Generic mfg.
Biomarker, Retrospective data, Journal: Prognostic factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer: a retrospective study. (Pubmed Central) - Sep 29, 2022
In this review, we will discuss about the molecular signaling pathways involved in major angiogenic diseases in detail. These findings can serve as important factors when selecting the first-line chemotherapy regimen for patients with mCRC.
- | quemliclustat (AB680) / Arcus Biosci, Gilead
Journal, PD(L)-1 Biomarker, IO biomarker: Additive effect of CD73 inhibitor in colorectal cancer treatment with CDK4/6 inhibitor through regulation of PD-L1. (Pubmed Central) - Sep 29, 2022
P2
These findings can serve as important factors when selecting the first-line chemotherapy regimen for patients with mCRC. In this study, we demonstrated that a novel combination therapy of AB680 and palbociclib may be advantageous for the treatment of CRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: c-Met Signaling as a Therapeutic Target in Head and Neck Cancer. (Pubmed Central) - Sep 29, 2022
Inhibition of the c-Met pathway may subvert oncogenesis within the tumor-intrinsic compartment, blocking tumoral proliferation, invasion, migration, and metastasis, or the tumor-extrinsic compartment, modulating the immunosuppressive tumor microenvironment. This review discusses the rationale and current drug development strategies for targeting c-Met or its exclusive ligand hepatocyte growth factor (HGF) in HNSCC.
- | Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell Carcinoma. (Pubmed Central) - Sep 29, 2022
However, correlative biomarker analyses identified that trends for better overall survival with palbociclib and cetuximab were observed in certain prespecified subsets; the largest reduction in risk of death with palbociclib versus placebo and cetuximab occurred in the subset with CDKN2A mutations. Several phase II-III trials are underway investigating palbociclib in biomarker-selected patients with HPV-unrelated locally advanced or recurrent or metastatic HNSCC.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Review, Journal: Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy. (Pubmed Central) - Sep 29, 2022
In addition, some ncRNAs that are involved in the regulation of signaling pathways or genes related to anti-EGFR resistance, but need to be further verified by resistance experiments were also included in this review, thereby providing more ideas and basis for ncRNAs as CRC prognostic markers and anti-EGFR therapy sensitizers. Video Abstract.
- | Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Trial completion date, Metastases: BERING CRC: BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment (clinicaltrials.gov) - Sep 29, 2022
P=N/A, N=500, Recruiting, Sponsor: Pierre Fabre Pharma GmbH
Video Abstract. Trial completion date: Sep 2026 --> Jan 2027
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial. (clinicaltrials.gov) - Sep 29, 2022
P2, N=43, Completed, Sponsor: AIO-Studien-gGmbH
Trial completion date: Sep 2026 --> Jan 2027 Active, not recruiting --> Completed
- | Photofrin (porfimer sodium) / Advanz Pharma
Trial primary completion date, Metastases: Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (clinicaltrials.gov) - Sep 28, 2022
P2, N=82, Recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Trial primary completion date: Aug 2022 --> Aug 2023
- | Enrollment change, Checkpoint inhibition, IO biomarker, Metastases: ECOG-ACRIN EA3202: Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (clinicaltrials.gov) - Sep 28, 2022
P2/3, N=430, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2022 --> Aug 2023 N=216 --> 430
- || Ibrance (palbociclib) / Pfizer
Enrollment open: Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies (clinicaltrials.gov) - Sep 26, 2022
P2, N=35, Recruiting, Sponsor: Pfizer
N=216 --> 430 Not yet recruiting --> Recruiting
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
P2 data, Journal: Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial. (Pubmed Central) - Sep 25, 2022
In the bevacizumab arm, a significant difference in RFS existed between the low and high TRG groups, while in the cetuximab arm, for TRG, mTRG, and DH, the low and absent/rare groups demonstrated significantly longer RFS than the high and focal/diffuse groups, respectively. TRG could estimate RFS in patients who underwent liver metastasectomy after bevacizumab or cetuximab chemotherapy.
- | Akalux (cetuximab sarotalocan) / Rakuten Medical, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, HEOR: Quality-of-Life Evaluation of Patients with Unresectable Locally Advanced or Locally Recurrent Head and Neck Carcinoma Treated with Head and Neck Photoimmunotherapy. (Pubmed Central) - Sep 25, 2022
For patients with unresectable LA/LR-HNC, HN-PIT provided good local control without decreasing the QOL. The addition of HN-PIT to conventional head and neck carcinoma treatment may lead to the prolongation of OS in head and neck carcinoma.
- || Retrospective data, Review, Journal: Comparison of Second-Line Treatments for Patients with Platinum-Resistant Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis. (Pubmed Central) - Sep 25, 2022
Afatinib presented a better PFS and ORR than the SOC. Compared with afatinib, the PD-1 inhibitor had a better OS but a worse PFS.
- || Review, Journal, PARP Biomarker, IO biomarker: Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now? (Pubmed Central) - Sep 24, 2022
Monoclonal antibodies include bevacizumab, cetuximab, pertuzumab, trastuzumab, and seribantumab...In conclusion, the tyrosine kinases remain attractive targets for treating ovarian cancers. Future development will need to consider effective drug combination, frequency of target, and developing predictive biomarker.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Bioradiotherapy with Cetuximab May Reduce the Risk of Neck Node Relapse in Locoregionally Advanced Laryngeal Glottic Carcinoma: May HER1-Profile Be Useful in the Bioselection of Patients? (Pubmed Central) - Sep 24, 2022
BioRT with cetuximab showed a reduction in the risk of lymph node relapse, particularly in the case of HER1 positive tumors, and it allowed to achieve a higher rate of functional larynx preservation and a higher salvageability compared with upfront surgery. HER1 analysis could be clinically useful in the bioselection of tumors that may benefit from BioRT with cetuximab, particularly in those with neck node metastatic propensity.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure. (Pubmed Central) - Sep 24, 2022
EAI045 and cetuximab combined induce tumor regression in mouse models of EGFR-mutant lung cancer...Our results show that blood-brain barrier ABCB1 can markedly limit EAI045 brain accumulation. Moreover, elacridar coadministration can effectively reverse this process.